Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(15 sites)

United States

University of California San Francisco UCSF, San Francisco, California

ABMED Clinical Research Corp, Cape Coral, Florida

Ann & Robert H. Lurie Children's Hospital, Chicago, Illinois

National Institute of Child Health and Human Development, Bethesda, Maryland

Texas Valley Clinical Research, Weslaco, Texas

Belgium

UZ Brussel, Jette, Brussels Capital

Bulgaria

Multiprofile Hospital for Active Treatment Sveta Marina EAD, Varna

France

Hospital Necker Enfants Malades, Paris

Robert Debre Hospital, Paris

CHU Bicetre APHP Paris Saclay, Paris

Italy

Aziendal Ospedaliero Universitaria Pisana Presidio Ospedale di Cisanello, Pisa, PI

Ospedale Bambino Gesu, Roma

Slovenia

University Clinical Center Ljubljana, Ljubljana

United Kingdom

Alder Hey Childrens NHS Foundation Trust, Liverpool

The Royal London Childrens Hospital, London